CL2023000191A1 - Inhibidores de factores del complemento y usos de los mismos - Google Patents

Inhibidores de factores del complemento y usos de los mismos

Info

Publication number
CL2023000191A1
CL2023000191A1 CL2023000191A CL2023000191A CL2023000191A1 CL 2023000191 A1 CL2023000191 A1 CL 2023000191A1 CL 2023000191 A CL2023000191 A CL 2023000191A CL 2023000191 A CL2023000191 A CL 2023000191A CL 2023000191 A1 CL2023000191 A1 CL 2023000191A1
Authority
CL
Chile
Prior art keywords
complement factor
factor inhibitors
disclosed
disease
compounds
Prior art date
Application number
CL2023000191A
Other languages
English (en)
Inventor
R Artis Dean
Philip Leslie Colin
Biagio Mileo Luca
Beato Claudia
Sorana Federico
Di Guglielmo Bruno
Padroni Chiara
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CL2023000191A1 publication Critical patent/CL2023000191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula I y II y sales farmacéuticamente aceptables de los mismos. También se divulgan métodos para tratar un trastorno neurodegenerativo, una enfermedad inflamatoria, una enfermedad autoinmunitaria, una enfermedad oftalmológica o un trastorno metabólico usando los compuestos divulgados en el presente documento.
CL2023000191A 2020-07-20 2023-01-19 Inhibidores de factores del complemento y usos de los mismos CL2023000191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063054064P 2020-07-20 2020-07-20

Publications (1)

Publication Number Publication Date
CL2023000191A1 true CL2023000191A1 (es) 2023-09-08

Family

ID=79729495

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000191A CL2023000191A1 (es) 2020-07-20 2023-01-19 Inhibidores de factores del complemento y usos de los mismos

Country Status (17)

Country Link
US (2) US11814404B2 (es)
EP (1) EP4185592A1 (es)
JP (1) JP2023534974A (es)
KR (1) KR20230041758A (es)
CN (2) CN116261564A (es)
AR (1) AR123011A1 (es)
AU (1) AU2021311455A1 (es)
BR (1) BR112023001007A2 (es)
CA (1) CA3186022A1 (es)
CL (1) CL2023000191A1 (es)
CO (1) CO2023000683A2 (es)
IL (1) IL299840A (es)
MX (1) MX2023000919A (es)
PE (1) PE20231435A1 (es)
TW (1) TW202216168A (es)
UY (1) UY39331A (es)
WO (1) WO2022020244A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244234T1 (de) 1997-04-24 2003-07-15 Ortho Mcneil Pharm Inc Substituierte imidazole zur behandlung von entzündlichen krankheiten
EP1971664B1 (en) * 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
US8221907B2 (en) 2007-07-07 2012-07-17 Idemitsu Kosan Co., Ltd. Chrysene derivative and organic electroluminescent device using the same
WO2015003146A1 (en) * 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) * 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
KR101981245B1 (ko) 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
CN111683935B (zh) 2018-06-11 2023-09-29 株式会社Lg化学 杂环化合物及包含其的有机发光器件
WO2020032428A1 (ko) * 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574910B (zh) * 2018-12-19 2021-07-02 山西大学 一种咔唑衍生物mcab及其制备方法和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
CN113045585A (zh) 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用

Also Published As

Publication number Publication date
MX2023000919A (es) 2023-04-19
IL299840A (en) 2023-03-01
CA3186022A1 (en) 2022-01-27
CN116947903A (zh) 2023-10-27
US20220048930A1 (en) 2022-02-17
TW202216168A (zh) 2022-05-01
JP2023534974A (ja) 2023-08-15
UY39331A (es) 2022-02-25
PE20231435A1 (es) 2023-09-14
AU2021311455A1 (en) 2023-02-16
US20240109920A1 (en) 2024-04-04
WO2022020244A1 (en) 2022-01-27
US11814404B2 (en) 2023-11-14
KR20230041758A (ko) 2023-03-24
EP4185592A1 (en) 2023-05-31
AR123011A1 (es) 2022-10-19
CN116261564A (zh) 2023-06-13
BR112023001007A2 (pt) 2023-03-28
CO2023000683A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2019002240A1 (es) Dendrímeros terapéuticos.
UY37098A (es) Moduladores de ror-gamma
DOP2018000150A (es) Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje
CL2020000911A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
CO2020013840A2 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
CL2022001183A1 (es) Formas de sal de un receptor del componente c5a del complemento
CL2021000329A1 (es) Compuestos útiles en terapia del vih
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a
CU20220025A7 (es) Inihibidores del factor d del complemento para administración oral
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
AR115731A1 (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de quinasas irak4
CO2023000683A2 (es) Inhibidores de factores del complemento y usos de los mismos
AR111063A1 (es) Dendrímeros terapéuticos
CO2024001004A2 (es) Compuestos de sulfonimidamida y usos de los mismos
AR126554A1 (es) Composiciones y métodos para la inhibición de ras